Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Interferon in relapsing-remitting multiple sclerosis.
Dilantin
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Thrombotic microangiopathy associated with use of interferon-beta.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.
Rituximab product approval information - Licensing action
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
RTL therapy for multiple sclerosis: a Phase I clinical study.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Zebrafish myelination: a transparent model for remyelination?
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Visualization of myelination in GFP-transgenic zebrafish.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
Alemtuzumab and multiple sclerosis: therapeutic application.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses.
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR.

Pages